Literature DB >> 23897487

Characteristics of patients diagnosed with both melanoma and renal cell cancer.

Michael R Abern1, Matvey Tsivian, Christopher L Coogan, Howard L Kaufman, Thomas J Polascik.   

Abstract

BACKGROUND: Patients with renal cell carcinoma (RCC) and malignant melanoma (MM) have an increased risk of additional malignancies. We identified characteristics of MM and RCC associated with a patient developing both cancers.
METHODS: A total of 147,656 cases of RCC and 225,548 of MM submitted to the Surveillance, Epidemiology, and End Results database between 1973 and 2008 were analyzed. Standardized incidence ratios (SIR) with 95 % confidence intervals (CI) were calculated for MM after RCC and vice versa. Clinical and pathological characteristics were compared between patients with RCC or MM only and with both cancers using multivariable proportional hazards and competing risks regression models.
RESULTS: Overall 1,241 patients developed both cancers. The crude incidence rates of RCC in patients with a prior MM diagnosis and vice versa were 5.2 and 9.4 per 10,000 person-years, respectively. There was an excess of MM in RCC patients (SIR 1.45, CI 1.34-1.57) and of RCC in MM patients (SIR 1.34, CI 1.25-1.43). Median years from RCC to MM diagnosis was 4.3 (2.0-7.8) and from MM to RCC 4.7(2.3-9.9). Patients with a history of MM had more papillary RCC (10.2 vs. 4.8 %, p = 0.01) and were more likely to be female (25.9 vs. 20.5 %, p < 0.001). On multivariable analyses, ocular MM was independently associated with subsequent RCC (HR 1.76 CI 1.24-2.49), as were increasing age, and male sex.
CONCLUSIONS: We confirmed a bidirectional association between RCC and MM. A history of MM was found to be associated with papillary RCC and advanced RCC. Ocular MM predicted an increased risk of RCC diagnosis. Further research is warranted into the mechanisms responsible for the association between RCC and MM.

Entities:  

Mesh:

Year:  2013        PMID: 23897487     DOI: 10.1007/s10552-013-0267-0

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  3 in total

1.  Long Term Administration of Nivolumab for Metastatic Melanoma: A Case Report.

Authors:  Adela-Raluca Oprea; Arnaud Benas; Andrei Havasi; Alecsandra Gorzo; Stefan Spinu; Daniel Sur; Claudia Burz
Journal:  Cureus       Date:  2022-06-27

2.  The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma.

Authors:  Jean-Noël Hubert; Voreak Suybeng; Maxime Vallée; Tiffany M Delhomme; Eve Maubec; Anne Boland; Delphine Bacq; Jean-François Deleuze; Fanélie Jouenne; Paul Brennan; James D McKay; Marie-Françoise Avril; Brigitte Bressac-de Paillerets; Estelle Chanudet
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

3.  Identification of genes and pathways leading to metastasis and poor prognosis in melanoma.

Authors:  Xin Zhang; Wandong Wang; Yun Wang; Guan Jiang
Journal:  Aging (Albany NY)       Date:  2021-09-28       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.